Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Jagsonpal Pharmaceuticals Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Jagsonpal Pharmaceuticals Ltd trades at a P/E of 33.50× and P/B of 5.37×.
Valuation
Profitability
Growth
Financial Health
Jagsonpal Pharmaceuticals Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Jagsonpal Pharmaceuticals Ltd, switchable between annual and quarterly views, consolidated or standalone.
Jagsonpal Pharmaceuticals Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,421.94 Cr and reported EPS of ₹6.31.
Jagsonpal Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at Jagsonpal Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Jagsonpal Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Jagsonpal Pharmaceuticals Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Jagsonpal Pharmaceuticals Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Jagsonpal Pharmaceuticals Ltd's investment case rests on 9 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
ROCE at 23.00% and ROE at 18.60% indicate efficient capital utilization and strong returns for shareholders, reflecting robust operational performance.
The company reported a significant 23.10% increase in quarterly sales and a substantial 38.60% rise in quarterly net profit, demonstrating strong recent business momentum.
With a very low debt-to-equity ratio of 0.04, Jagsonpal Pharmaceuticals maintains a strong and conservative financial position, minimizing financial risk.
A substantial promoter holding of 67.6% signals strong confidence from the management in the company's future prospects and long-term value creation.
The company offers a dividend yield of 1.12%, providing a steady income stream to investors, which can be appealing in the current market environment.
What can break it.
The stock is trading near its 52-week low of 192.85, a substantial drop from its 52-week high of 820.10, indicating considerable price volatility and potential investor concern.
A price-to-book value of 6.15 suggests the stock is trading at a premium relative to its intrinsic asset value, which might limit upside potential for value investors.
While recent quarterly profits are strong, historical data shows inconsistent net profit figures, with a notable dip to 4.00 in 2023-12-01 from 10.00 in 2022-09-01.
DII holding is very low at 0.08%, and FII holding, while increasing, is still modest at 2.12%, suggesting less institutional conviction compared to peers.
The company faces stiff competition from larger, more established players like Sun Pharma, Divi's Lab, and Cipla, which have significantly higher market caps and resources.
What would change my mind.
Trim if P/E re-rates above 44. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 3.46. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 12%. The operating engine is no longer compounding capital efficiently.
Jagsonpal Pharmaceuticals Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Jagsonpal Pharmaceuticals Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Jagsonpal Pharmaceuticals Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Jagsonpal Pharmaceuticals Ltd — derived from the live tape, not yesterday's close.
Jagsonpal Pharmaceuticals Ltd last traded at ₹211.39 with an intraday range of ₹210.5–₹219.36 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹211.39| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 234.72 | +23.33 | +11.04% |
| R3 | 225.86 | +14.47 | +6.85% |
| R2 | 222.61 | +11.22 | +5.31% |
| R1 | 217.00 | +5.61 | +2.65% |
| PIVOT | 213.75 | 2.36 | 1.12% |
| CURRENT | 211.39 | — | — |
| S1 | 190.42 | -20.97 | -9.92% |
| S2 | 199.28 | -12.11 | -5.73% |
| S3 | 204.89 | -6.50 | -3.07% |
| S4 | 208.14 | -3.25 | -1.54% |
JAGSNPHARM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 210.93 ~ 214.9
Trading Inside opening range
Jagsonpal Pharmaceuticals Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Jagsonpal Pharmaceuticals Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Jagsonpal Pharmaceuticals Ltd stood at 37.9% of traded volume, against a 20-day average of 50.8%.
Jagsonpal Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Jagsonpal Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Jagsonpal Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 94 documents below.
Updates
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited…
Disclosure under SEBI Takeover Regulations
Infinity Holdings has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Closure of Buy Back
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Closure of Buy Back with effect from Jun 02, 2026
Copy of Newspaper Publication
Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Copy of Newspaper Publication
Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Press Release
Jagsonpal Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Jagsonpal Pharmaceuticals has declared, sequenced by announce and record date.
Jagsonpal Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Jagsonpal Pharmaceuticals Ltd: business, sector, key facts.
What Jagsonpal Pharmaceuticals Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Jagsonpal Pharmaceuticals Ltd operates in the Healthcare, listed as NSE: JAGSNPHARM, BSE: 507789.
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is a pharmaceutical company primarily operating in India but also with an international presence. Their core business revolves around the manufacturing, sale, and trading of pharmaceutical products and active pharmaceutical ingredients (APIs).
The company's product portfolio spans a variety of therapeutic areas, with a notable focus on gynecology, orthopedics, dermatology, and pediatrics. This specialization allows them to cater to a diverse range of patient needs and healthcare requirements.
JAGSNPHARM offers its products in multiple dosage forms, including tablets, softgels, injections, capsules, and syrups. This diverse range of delivery methods enables flexibility in addressing various patient preferences and treatment requirements. The variety of forms also suggests a broad range of active ingredients and formulations within their product lines.
Their customer base includes both healthcare professionals, such as doctors and pharmacists, and government institutions. This dual market approach signifies a robust and diversified distribution network, lessening dependence on any single customer segment. The inclusion of government institutions suggests a presence in public health initiatives and contracts.
Established in 1978 and headquartered in New Delhi, India, JAGSNPHARM benefits from a long operational history in the Indian pharmaceutical market. This longevity suggests established supply chains, manufacturing capabilities, and regulatory compliance.
Questions investors ask about Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
The current share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹211.39. Today, the stock has gained by ₹1.76 (0.84%), trading in a range of ₹210.5 to ₹219.36. The stock opened at ₹213.8 with a trading volume of 1,70,495 shares.
02Is Jagsonpal Pharmaceuticals Ltd stock a good investment for long-term?
Jagsonpal Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,421.94 crores, P/E ratio of 33.50, ROE of 16.70%, and ROCE of 23.00%. The dividend yield stands at 1.19%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Jagsonpal Pharmaceuticals Ltd stock?
The 52-week high price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹0, while the 52-week low is ₹0. Currently trading at ₹211.39, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Jagsonpal Pharmaceuticals Ltd stock at the current price?
Whether to buy Jagsonpal Pharmaceuticals Ltd stock at ₹211.39 depends on multiple factors. The stock is currently trading with a P/E ratio of 33.50 and P/B ratio of 5.37. Today's performance shows a gain of 0.84%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Jagsonpal Pharmaceuticals Ltd and when is the next dividend?
Jagsonpal Pharmaceuticals Ltd offers a dividend yield of 1.19%, which means for every ₹100 invested at the current price of ₹211.39, you can expect to receive approximately ₹1.19 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 33.50, P/B Ratio: 5.37, ROE: 16.70%, ROCE: 23.00%, Dividend Yield: 1.19%, EPS: ₹6.31, Book Value: ₹39.4, and Debt-to-Equity: 2.96. The company's market cap stands at ₹1,421.94 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Jagsonpal Pharmaceuticals Ltd stock performing today in the market?
Jagsonpal Pharmaceuticals Ltd stock opened at ₹213.8 and is currently trading at ₹211.39, showing a gain of ₹1.76 (0.84%). The intraday high is ₹219.36 and low is ₹210.5. The trading volume stands at 1,70,495 shares, indicating moderate market participation today.
08What is the P/E ratio of Jagsonpal Pharmaceuticals Ltd and what does it indicate?
Jagsonpal Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 33.50, which means investors are willing to pay ₹33.50 for every ₹1 of earnings. With an EPS of ₹6.31, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy